Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals' fourth-quarter revenue and outlook for 2025 topped analysts’ expectations. ... By Andrew Kessel. Published February 10, 2025. 04:30 PM EST. JHVEPhoto / Getty Images.

Vertex Pharmaceuticals (NASDAQ:VRTX) has been analyzed by 14 analysts in the last three months, ... Andrew Fein: HC Wainwright & Co. Raises: Buy: $500.00: $462.00: Matthew Harrison: Morgan Stanley: ...

Vertex Pharmaceuticals said it sees FY25 revenue of $11.75 billion to $12.00 billion, versus market estimates of $11.84 billion. Vertex Pharmaceuticals shares fell 2.5% to trade at $458.15 on Tuesday.

The latest international Vertex Pharmaceuticals Inc news and views from Reuters ... Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.